Aplus Biotechnology Corporation Limited (6918.TWO)
TWD 81.0
(-3.57%)
TWD 81.0
(-3.57%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | 159.1 Million | 60.64 Million | 52.95 Million | 112.21 Million | - |
| Net Income | 45.5 Million | 68.11 Million | 46.05 Million | 47.74 Million | - |
| Depreciation & Amortization | 26.38 Million | 24.86 Million | 21.42 Million | 25.48 Million | - |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | - | - | 1.71 Million | - | 8.8 Million |
| Change in working capital | -2.19 Million | -19.01 Million | -9.82 Million | 20.49 Million | - |
| Other non-cash items | 995 Thousand | 1.83 Million | 1.77 Million | 31.38 Million | - |
| Investing Cash Flow | -4.84 Million | -30.5 Million | -234.23 Million | 137.19 Million | - |
| Investments in PPE | -9.8 Million | -36.76 Million | -224.91 Million | -5.65 Million | - |
| Acquisitions | - | - | - | - | - |
| Investment purchases | - | - | - | 141.44 Million | -124.14 Million |
| Sales/Maturities of investments | - | - | - | 141.44 Million | - |
| Other Investing Activities | 4.95 Million | 6.26 Million | -9.32 Million | 1.4 Million | - |
| Financing Cash Flow | -69.17 Million | -98.81 Million | 197.22 Million | -57.78 Million | - |
| Debt repayment | -25.66 Million | -74.88 Million | -167.22 Million | -50.28 Million | - |
| Dividends payments | -21.12 Million | -15.23 Million | -14.32 Million | - | -13.78 Million |
| Common Stock Repurchased | -14.15 Million | - | - | - | - |
| Common Stock Issuance | - | - | 54.66 Million | - | 32.49 Million |
| Other Financing Activities | 1.27 Million | 1.12 Million | -1.01 Million | 2.22 Million | - |
| Accounts receivables | 4.38 Million | - | - | - | - |
| Accounts payables | - | - | - | - | - |
| Inventory | 9.26 Million | 7.08 Million | -24.39 Million | 32.45 Million | - |
| Other working capital | -15.84 Million | - | - | - | - |
| Cash at beginning of period | 237.68 Million | 305.09 Million | 289.31 Million | 100.37 Million | - |
| Cash at end of period | 319.06 Million | 237.68 Million | 305.09 Million | 289.31 Million | - |
| Capital Expenditure | -9.8 Million | -36.76 Million | -224.91 Million | -5.65 Million | - |
| Effect of forex changes on cash | -3.69 Million | 1.26 Million | -165 Thousand | -2.68 Million | - |
| Net cash flow / Change in cash | 81.37 Million | -67.4 Million | 15.78 Million | 188.93 Million | - |
| Free Cash Flow | 149.29 Million | 23.87 Million | -171.95 Million | 106.55 Million | - |
| Breakdown | 2023 FY | 2022 FY | 2021 FY | 2020 FY | 2019 FY |
|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - |
| Net Income | 45.5 Million | 68.11 Million | 46.05 Million | 47.74 Million | - |
| Depreciation & Amortization | 26.38 Million | 24.86 Million | 21.42 Million | 25.48 Million | - |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | - | - | 1.71 Million | - | 8.8 Million |
| Change in working capital | -2.19 Million | -19.01 Million | -9.82 Million | 20.49 Million | - |
| Other non-cash items | 995 Thousand | 1.83 Million | 1.77 Million | 31.38 Million | - |
| Investing Cash Flow | -4.84 Million | -30.5 Million | -234.23 Million | 137.19 Million | - |
| Investments in PPE | -9.8 Million | -36.76 Million | -224.91 Million | -5.65 Million | - |
| Acquisitions | - | - | - | - | - |
| Investment purchases | - | - | - | 141.44 Million | -124.14 Million |
| Sales/Maturities of investments | - | - | - | 141.44 Million | - |
| Other Investing Activities | 4.95 Million | 6.26 Million | -9.32 Million | 1.4 Million | - |
| Financing Cash Flow | -69.17 Million | -98.81 Million | 197.22 Million | -57.78 Million | - |
| Debt repayment | -25.66 Million | -74.88 Million | -167.22 Million | -50.28 Million | - |
| Dividends payments | -21.12 Million | -15.23 Million | -14.32 Million | - | -13.78 Million |
| Common Stock Repurchased | -14.15 Million | - | - | - | - |
| Common Stock Issuance | - | - | 54.66 Million | - | 32.49 Million |
| Other Financing Activities | 1.27 Million | 1.12 Million | -1.01 Million | 2.22 Million | - |
| Accounts receivables | - | - | - | - | - |
| Accounts payables | - | - | - | - | - |
| Inventory | 9.26 Million | 7.08 Million | -24.39 Million | 32.45 Million | - |
| Other working capital | - | - | - | - | - |
| Cash at beginning of period | 237.68 Million | 305.09 Million | 289.31 Million | 100.37 Million | - |
| Cash at end of period | 319.06 Million | 237.68 Million | 305.09 Million | 289.31 Million | - |
| Capital Expenditure | -9.8 Million | -36.76 Million | -224.91 Million | -5.65 Million | - |
| Effect of forex changes on cash | -3.69 Million | 1.26 Million | -165 Thousand | -2.68 Million | - |
| Net cash flow / Change in cash | 81.37 Million | -67.4 Million | 15.78 Million | 188.93 Million | - |
| Free Cash Flow | 149.29 Million | 23.87 Million | -171.95 Million | 106.55 Million | - |
HE8
PRBCF
ABG
6996
0122
0H9G